Key result
Elevated H-FABP in patients with acute coronary syndrome is associated with higher odds of all-cause mortality (OR 5.68; 95% CI 3.98-8.09), MACE, heart failure hospitalization, and recurrent MI.
Why the study?
The prognostic significance of elevated heart-type fatty acid-binding protein in acute coronary syndrome remains uncertain.
Does elevated H-FABP predict all-cause mortality, MACE, HF hospitalisation, and recurrent MI in adults with confirmed or suspected acute coronary syndrome?
Meta-Analysis
Does elevated H-FABP predict all-cause mortality, MACE, HF hospitalisation, and recurrent MI in adults with confirmed or suspected acute coronary syndrome?
Elevated H-FABP is associated with significantly increased risks of mortality, MACE, HF hospitalisation, and recurrent MI in patients with ACS, though its independent prognostic value remains unclear.
H-FABP shows early diagnostic promise in ACS but lacks support for routine risk stratification; leaves open its incremental value beyond troponin.
Introduction Heart‐type fatty acid‐binding protein (H‐FABP) is rapidly released following myocardial injury, but its prognostic significance in acute coronary syndrome (ACS) remains uncertain. We evaluated the association between elevated H‐FABP and adverse clinical outcomes in confirmed or suspected ACS. Methods PubMed, Embase, CENTRAL, Web of Science and Scopus were searched from inception to 30 August 2026 without date restriction. Studies assessing diagnostic and/or prognostic relevance of circulating H‐FABP in adults with confirmed or suspected ACS were eligible. Prognostic outcomes included all‐cause mortality, major adverse cardiovascular events (MACE), heart failure (HF)–related hospitalisation and recurrent myocardial infarction (MI). Risk of bias was assessed using QUIPS. Crude odds ratios (ORs) from extractable 2 × 2 event data were pooled using inverse‐variance random‐effects models with restricted maximum‐likelihood estimation. Results Twelve studies were included, with five contributing to meta‐analysis. Elevated H‐FABP was associated with higher odds of all‐cause mortality (OR 5.68; 95% CI 3.98–8.09; I 2 = 30 % ), MACE (OR 4.56; 95% CI 1.97–10.55; I 2 = 47 % ), HF‐related hospitalisation (OR 4.29; 95% CI 2.94–6.26; I 2 = 0 % ) and recurrent MI (OR 1.65; 95% CI 1.15–2.37; I 2 = 0 % ). Pooled estimates were unadjusted; seven studies were synthesised narratively. Conclusion Elevated H‐FABP is associated with adverse outcomes in ACS, but current evidence does not establish independent prognostic value. Further prospective studies should determine whether H‐FABP adds predictive value beyond established clinical and biochemical risk markers.
No takes yet. Share an insight, caveat, or question.
Elmewafy et al. (2026) conducted a meta-analysis in Acute coronary syndrome (ACS). Elevated Heart-type fatty acid-binding protein (H-FABP) vs. Non-elevated H-FABP was evaluated on All-cause mortality (OR 5.68, 95% CI 3.98-8.09). Elevated H-FABP in patients with acute coronary syndrome is associated with higher odds of all-cause mortality (OR 5.68; 95% CI 3.98-8.09), MACE, heart failure hospitalization, and recurrent MI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: